Different Potent Glucocorticoids, Different Routes of Exposure but the Same Result: Iatrogenic Cushing’s Syndrome and Adrenal Insufficiency

Ayla Güven

University of Health Sciences Turkey, Istanbul Zeynep Kamil Women and Children Diseases Hospital, Clinic of Pediatric Endocrinology, Istanbul, Turkey

What is already known on this topic?

The most common cause of Cushing’s syndrome (CS) in childhood is the administration of high doses of synthetic glucocorticoids (GC) for treatment purposes or misuse of these steroids.

What this study adds?

This is the largest series presenting iatrogenic CS (ICS) and adrenal insufficiency (AI) caused by potent steroids in childhood. AI is a rare cause of hypercalcemia in infancy and childhood but hypercalcemia was detected in two infants of fourteen patients in this study. In addition, an infant with ICS had exposure to a cream and the patient’s urine and blood steroid analyses revealed exposure to high-dose steroids.

Abstract

Objective: Potent glucocorticoids (GC) cause iatrogenic Cushing’s syndrome (ICS) due to suppression of hypothalamo-pituitary-adrenal (HPA) axis and may progress to adrenal insufficiency (AI). The aim was to review the clinical and laboratory findings of patients with ICS and to investigate other serious side effects.

Methods: The possibility of AI was investigated by low-dose adrenocorticotrophic hormone test. Hydrocortisone was started in patients with adrenal failure.

Results: Fourteen patients (five boys) with ages ranging from 0.19 to 11.89 years were included. The duration of GC exposure ranged from 1 to 72 months. Ten patients were prescribed topical GC and the rest had oral exposure. Moon face and abdominal obesity were detected in all patients. At presentation, 12 of 14 had AI and two infants had hypercalcemia and nephrocalcinosis. Of 11 patients, ultrasonography revealed hepatosteatosis in five. A cream for diaper dermatitis was used in one infant and the active ingredient was listed as panthenol. However, blood and urine steroid analyses revealed that all endogenous steroids were suppressed. Median (range) time to normalization of HPA axis function was 60 (30-780) days.

Conclusion: The majority (85%) of patients had life-threatening AI and two patients had hypercalcemia. These results highlight the serious side-effects of inappropriate use of potent GCs, especially in infants. The recovery of the HPA axis in children might take as long as three years. Parents should be informed regarding the possibility of some products containing unlisted synthetic GC and to be aware of their side effects.

Keywords: Cushing’s syndrome, adrenal insufficiency, glucocorticoids, adverse effect, hypercalcemia, non-alcoholic fatty liver disease
Introduction

Cushing’s syndrome (CS) is very rare in childhood and the most common cause is the administration of high doses of synthetic glucocorticoids (GC) for treatment purposes or misuse of these steroids (1). GC are one of the most widely used drugs in the treatment of numerous diseases, including hematological diseases, oncological malignancies, respiratory system diseases, rheumatologic diseases, neurological diseases, kidney diseases, organ transplantations and adrenal insufficiency (AI). As the potency and duration of administration of GC increase, the risk of serious side effects also increases. These side effects include hypercortisolism, hypothalamo-pituitary-adrenal axis (HPA) suppression, non-alcoholic fatty liver disease (NAFLD), osteoporosis, or even adrenal atrophy. Hypercortisolism due to exogenous steroids is known as iatrogenic CS (ICS) (2).

Synthetic GC exogenously given via oral, iv, intramuscular, intra-articular, topical, inhaled, intra-ocular or intra-nasal routes can cause ICS. It is known that GC, which are frequently administered orally and topically in childhood, cause ICS (3,4). In particular, application of topical steroids to the diaper region of an infant may lead to CS and subsequent AI (5). Such use of exogenous GC may even facilitate the spread of infectious disease through suppression of immune function that might be fatal (6). In addition to potent steroids, long-term and high-dose administration of low-potency GC such as hydrocortisone (HC), prednisolone (PZ) and methylprednisolone (MPZ), which are frequently used in the treatment of several diseases, may cause similar side effects (7,8).

In this article, the clinical and laboratory findings of 14 patients with ICS due to oral GC treatment prescribed by physicians for treatment purposes and topical steroids applied by their parents are presented. The aim of this study was to review the clinical and laboratory findings of patients with ICS and to investigate and demonstrate other rare but important side effects.

Methods

Patients

In this retrospective study, all data was obtained from patients’ medical records. Only those exposed to high-dose potent GC were included in this study. Anthropometric measurements were recorded. Body mass index (BMI) of the patients was calculated. Height, weight and BMI-standard deviation (SD) score (SDS) of the patients were calculated using “Child metrics” (9). Fourteen patients including nine girls and five boys, aged between 0.19 and 11.89 years, were identified. All patients had been given a high dose of moderate to high potency GC either orally or topically. Those who were exposed to topical potent GC for more than a week or had used oral potent steroids for more than 15 days were included in the study.

Ten patients had been given topical GC, such as clobetasol-propionate, diflucortolone-valerate, MPZ-aceponate and betamethasone exposure. The remaining four had been given MPZ and PZ orally.

The mother of one patient (case 12) had been using an ointment to prevent diaper dermatitis since birth, believing that it contains panthenol. The manufacturer stated that there was no GC in the cream.

In addition to the side effects of steroids in these patients, AI due to suppression of the HPA axis, frequently seen in ICS patients, was investigated. Low-dose adrenocorticotrophic hormone (LD-ACTH) test was performed to investigate AI in all patients except two. These two were not tested because the family of one did not consent and the other patient, with severe thrombocytopenia, could not be tested since intravenous (iv) Synacthen was not available at the time.

The equivalent daily dose (EDD) of GC exposure was calculated in five patients, according to HC equivalence. However, the EDD could not be predicted for those who were exposed to topical steroids. The potency of GCs according to HC was determined (2).

Ophthalmologic examination was performed in seven patients and abdominal ultrasonography was performed in 12 patients. Detailed clinical information about all patients is given in supplemental file.

Laboratory Investigations

After an overnight fast (in children for at least eight hours and in infants for at least six hours) blood samples were taken. Serum concentrations of glucose, calcium, phosphorus, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, total cholesterol (TC), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C) and triglyceride (TG) were measured. Fasting concentrations of serum TC, TG and LDL-C were considered high when these were above 200 mg/dL, 100 mg/dL and 130 mg/dL, respectively. The desirable level of HDL-C was above 40 mg/dL, so the cut-off point was accepted as 40 mg/dL. Serum parathyroid hormone, magnesium, 25-hydroxyvitamin D [25-(OH)D$_3$] and 1,25-dihydroxyvitamin D [1,25-(OH)$_2$D$_3$] levels were measured in the two patients with hypercalcemia. Spot urine calcium and creatinine ratio also was calculated.
A 24-hour urine sample and a morning fasting blood sample were obtained from case 12 before treatment was initiated. Blood steroid analysis was performed at Marmara University Medical Faculty Hospital, Biochemistry Laboratory and high-performance liquid chromatography was used in the analysis. In addition, urine steroid metabolites of this infant were measured using quantitative gas chromatography-mass spectrometry in selected ion monitoring at the University of Birmingham, College of Medical and Dental Sciences, Steroid Metabolome Analysis Core, Institute of Metabolism and System Research.

A LD (1 μg) ACTH test was performed in 12 patients (Synacthen 250 μg, iv, Novartis, Basel, Switzerland) for adrenal investigation. A stimulated peak cortisol level on LD-ACTH test of more than 500 nmol/L (equivalent 18 μg/dL) was considered adequate (10). Lower levels of cortisol (<500 nmol/L) demonstrate AI. In patients who received HC, MPZ or PR with a drug reduction scheme, the LD-ACTH test was performed 4-7 days after the discontinuation of the drug.

Therapy and Follow-up

Nine of the patients had been treated with HC (15-20 mg/m²/day), and one patient with PR (4-5 mg/m²/day) for 2-3 weeks for prevention of GC withdrawal syndrome. Case 1 had been treated with MPZ (15 mg/m²/d), since a total of 5000 mg MPZ po was given over five days for severe immune thrombocytopenic purpura before admission. HC, MPZ or PR doses were gradually decreased over the 2-3 weeks. According to the age of the patients, LD-ACTH test was re-performed with an interval of one to two months. The HPA axis was considered to be recovered when stimulated cortisol increased above 18 μg/dL.

Written informed consent was obtained from the parents. The hospital ethics committee approved this study (Zeynep Kamil Women and Children Diseases Training and Research Hospital Clinical Research Ethics Committee, 116/18.12.2019).

Statistical Analysis

All analysis was done using the Statistical Package for the Social Sciences, version 21 (IBM Inc., Armonk, NY, USA). In order to determine whether the data was normally distributed the Shapiro-Wilk method was used. Descriptive statistics of the data which were normally distributed are summarized as mean±SD. For non-parametric data summary is given as median (interquartile range: IQR). For all tests, a p-value of less than 0.05 was accepted as statistically significant.

Results

A clinical summary of the patients is given in Table 1. The median age was 1.76 (1.105) years (0.19-11.89). Mean BMI of the patients was 24.3 ± 7.8 kg/m², median height was 79.7 (80.23) cm and median weight was 12 (58.5) kg. Mean height SDS of the patients was -0.46 ± 1.32, weight SDS was 1.32 ± 2.1, and BMI SDS was 1.82 ± 2.0. Only one patient had short stature, a girl who received high dose MPZ orally for two years; all other patients had height or length within the expected range. At presentation, six patients (four girls) were obese and three were overweight. However, BMI SDS of the two infants were -1.44 and -1.63. Systolic and diastolic blood pressure was normal in all patients in whom blood pressure could be measured (mean systolic: 108 ± 15 mmHg and mean diastolic: 69 ± 4.9 mmHg).

Five patients were exposed to potent GCs orally, and nine patients via the transdermal route. Median duration of high dose GC exposure was 4 (22.1) (range 1-72) months. In five patients who were exposed orally the equivalent HC daily dose was 95 ± 78 mg/m²/d. However, the EDD could not be estimated in nine patients, since the amount applied to skin and its absorption could not be calculated.

Median basal ACTH and cortisol levels of the patients were 16.9 (22.91) pg/mL and 3.73 (6.37) mcg/dL, respectively. Mean stimulated cortisol was 8.55 ± 6.5 mcg/dL. At presentation, 100% of the infants were found to have AI, while overall 85% of patients had AI.

Persistent AI was detected in case 2 due to adrenal atrophy. On presentation the HPA axis was normal in two patients. However, HPA axis normalization time was not predicted in three patients because they were lost to follow up after initial discharge. In the remainder the normalization of the suppressed HPA axis occurred at a median of 60 (IQR 160; range 30-780) days in nine patients. Patients were followed for a median of 240 (825) days.

Although the majority of the patients’ transaminases were within normal range (AST 31.1 ± 14 IU and ALT 35.3 ± 23 IU), these were elevated in two patients. Mean fasting serum TG level was 131 ± 63 mg/dL. Hypertriglyceridemia was detected in six of nine patients whose fasting TG levels were measured. The youngest patient with hypertriglyceridemia was two months old. Hypercholesterolemia and increased LDL-C was found in the same two patients. Low HDL-C was detected in other two patients (Table 2). AI was detected in 12 patients with serum basal and/or stimulated cortisol (Table 2). Bilateral posterior segment cataract was detected in case 1 on ophthalmologic examination. Abdominal
Table 1. Clinical findings of the patients with iatrogenic Cushing's syndrome at presentation

| Patient's number | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|------------------|---|---|---|---|---|---|---|
| Age (years)      | 12 | 0.21 | 9 | 0.56 | 0.41 | 2.45 | 1.08 |
| Gender           | F | M | F | F | M | M |
| Complaint        | CS suspicion during treatment of ITP | Puffiness on the face and abdomen | Maculopapular rash | Pubic hair | Rapid weight gain | Hair on the face | Widespread hypertrichosis |
| Causes of exposure and corticosteroid (CS) type | Prednisolone was given by the pediatrician before congenital cataract surgery | MPZ was given by the pediatrician for the treatment skin rashes | Diffucortolone valerate 0.3% and isonazol nitrate containing cream was used by her mother for the treatment of diaper dermatitis | Diffucortolone valerate 0.3% and isonazol nitrate containing cream was used by her mother for the treatment of diaper dermatitis | Clobetasol propionate 0.05% containing cream was used by his mother for the treatment of diaper dermatitis | Clobetasol propionate 0.05% containing cream was used by his mother for the treatment of diaper dermatitis |
| Duration of exposure | 24 months | 1.6 months | 1 months | Since birth | Since birth | 7 months | 2 months |
| CS potency/ HC equivalent dose, mg/m²/d | 5 times/180 | 4 times/148 | 5 times/165 | 100-150 times/ unpredictable | 100-150 times/ unpredictable | Up to 600 times/ unpredictable | Up to 600 times/ unpredictable |
| CS application route | Oral | Oral | Oral | Topical | Topical | Topical | Topical |
| Weight SDS       | 0.04 | 0.08 | 2.75 | 0.74 | 5.23 | -1.25 | -1.93 |
| Height SDS       | -3.35 | -1.33 | 0.6 | 0.03 | -0.22 | -1.47 | -1.21 |
| BMI SDS          | 1.98 | 1.57 | 2.9 | 0.91 | 6.21 | -0.3 | -1.63 |
| Physical examination findings | Buffalo hump, moon face, central obesity, purple striae | Moon face, central obesity, facial acne, oral and diaper candidiasis | Moon face, central obesity, widespread maculopapular rash in the whole body | Diffuse fine hair in the genital and sacral region | Moon face, central obesity, prominent skin folds | Moon face, central obesity, widespread hypertrichosis |
| Ophthalmologic examination | Bilateral posterior segment cataract | Right congenital cataract-left operated | Normal | Not performed | Not performed | Not performed | Not performed |
| Blood pressure (mmHg) | 120/75 | 110/60 |  |  |  |  |  |

F: female, M: male, CS: Cushing's syndrome, ITP: immune thrombocytopenic purpura, MPZ: methylprednisolone, BMI SDS: body mass index standard deviation score

ultrasonographic examination was performed in 11 patients. Five patients had hepatosteatosis. Two patients with hypercalcemia had nephrocalcinosis. In case 12, all adrenal steroids including androgen precursors and GC and their precursors were found to be decreased in the blood steroid profile. The urine results also showed low androgen precursors, GC and their precursors. TH-aldoosterone was slightly increased above normal, but others were normal or low. This profile was not consistent with endogenous CS, but compatible with exogenous administration of GC and subsequent suppression of endogenous GC production.

Discussion

In this study, clinical and laboratory results of children who were prescribed high-dose and potent GC by a doctor or
given them by their parents were investigated. In the present study, six of the 14 patients were younger than two years of age and five of them were exposed to high-dose GC via the transdermal route. Topical steroids were administered to these patients by their parents to prevent or treat diaper dermatitis. An LD-ACTH test was used in all of them except for case 5, and all revealed AI. In infants diagnosed with AI, low potency GC, such as PZ and MPZ, as well as high potency GCs, such as diflucortolone valerate 0.3% and clobetasol propionate 0.05% were used.

It is accepted that GCs, when used traditionally in doses less than 20 mg/day for less than three weeks, will not cause AI. However, it was reported that AI might be seen in adult patients who are exposed to prednisone or an equivalent dose of GCs at doses greater than 20-30 mg/day.

Table 1. Clinical findings of the patients with iatrogenic Cushing’s syndrome at presentation

| Gender | Age (years) | Gender | Age (years) | Gender | Age (years) | Gender | Age (years) |
|--------|-------------|--------|-------------|--------|-------------|--------|-------------|
| F      | 2           | M      | 2           | F      | 2           | F      | 2           |
| M      | 2 months   | F      | 1 month     | M      | 1 month     | F      | 3 months    |
| F      | 8           | M      | 3 years     | F      | Up to 600 times/ unpredictable | F      | 2 months |
| M      | 9           | F      | 6 years     | M      | 5 times     | F      | 5 times     |
| M      | 11          | F      | 2 years     | M      | 1 month     | M      | 5 times     |
| F      | 13          | F      | 1 month     | M      | Up to 600 times/ unpredictable | M      | 3 months |
| M      | 14          | F      | 2 months    | M      | 5 times     | F      | 2 months    |

| Weight gain | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|-------------|---|---|----|----|----|----|----|
| F           | 11.56 | 11.89 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| M           | 11.89 | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| M           | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| F           | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| M           | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| F           | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| M           | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| F           | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |

| Blood pressure | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|----------------|---|---|----|----|----|----|----|
| 110/70         | 130/70 | 92/70 | 110/70 | 130/70 | 92/70 | 110/70 | 130/70 |

| BMI SDS | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|---------|---|---|----|----|----|----|----|
| 2.43    | 2.27 | 4.06 | -2.1 | 2.26 | 2.12 | 1.79 |
| -1.24   | 1.37 | 0.58 | -1.7 | 1.45 | -0.03 | -0.01 |
| 3.12    | 2.08 | 3.74 | -1.44 | 1.58 | 2.47 | 2.22 |

| Ophthalmologic | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|---------------|---|---|----|----|----|----|----|
| Weight gain   | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| M             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| F             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| M             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| F             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| M             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| F             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| M             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |
| F             | 2 months | F | 11.56 | 10.88 | 0.46 | 0.19 | 11.4 | 6 |

Given the varied clinical presentations, the following are the findings:

- **BMI SDS**: 2.43
- **Blood pressure**: 110/70
- **Height SDS**: 2.43

For case 5, and all revealed AI. In infants diagnosed with AI, low potency GC, such as PZ and MPZ, as well as high potency GCs, such as diflucortolone valerate 0.3% and clobetasol propionate 0.05% were used.

It is accepted that GCs, when used traditionally in doses less than 20 mg/day for less than three weeks, will not cause AI. However, it was reported that AI might be seen in adult patients who are exposed to prednisone or an equivalent dose of GCs at doses greater than 20-30 mg/day.
day for more than five days (11). In addition, studies in adults have shown that high-dose GC therapy can cause HPA axis suppression even with a five day-treatment (12). Different results have been published regarding the recovery times from HPA axis suppression in children. In children with asthma who received PZ for five days, a full improvement in HPA axis was observed in 10 days, whereas in infants who received 12-25 weeks of high dose PZ, this period was 6-12 weeks (13,14). Moreover, it has been demonstrated that the HPA axis returns to normal within 1-2 weeks following discontinuation of PZ treatment for more than six months (15). In this study, it was found that the HPA axis returned to normal between 30 and 780 days.

AI might also occur in patients exposed to topical, inhaled, or intra-nasal GCs, depending on dose and potency (3,4). Patients in this series had been exposed to potent GCs for at least seven months. AI was inevitable due to the patients being children, and half of them were infants, and the vast majority was being treated with PZ.

Table 2. Laboratory findings in the patients

|                      | 1       | 2       | 3       | 4       | 5       | 6       | 7       |
|----------------------|---------|---------|---------|---------|---------|---------|---------|
| Fasting glucose md/dL| 348     | 91      | 168     | 99      | NA      | 99      |         |
| Insulin, μU/mL       | 17.07   |         | -       | -       | 3.5     | NA      |         |
| Ca, mg/dL            | 9.1     | 10.2    | 8.7     | 10.3    | NA      | 9.9     | 10.1    |
| P, mg/dL             | 4.8     | 5.9     | 3.5     | 5.5     | NA      | 5.4     | 5.5     |
| [25-(OH)D]₃, ng/mL   | 18.93   | 37.10   |         |         | NA      |         |         |
| [1,25-(OH) D₃], pg/mL|         | 2.30    |         |         | NA      |         |         |
| PTH                  | <3      |         |         |         |         |         |         |
| ALT, U/L             | 13      | 67      | 331     | 28      | NA      | 41      | 11      |
| AST, U/L             | 11      | 44      | 254     | 52      | NA      | 17      | 28      |
| ALP, U/L             | 99      |         | 180     |         | NA      | 325     | 308     |
| Total cholesterol, mg/dL | 186  | 361     | 142     | 149     | NA      |         |         |
| Triglyceride, mg/dL  | 186     | 143     | 270     | 75      | NA      | NA      | 69      |
| LDL, mg/dL           | 87      | 263     | 66      | 98      | NA      |         |         |
| HDL, mg/dL           | 62      | 69      | 22      | 36      | NA      |         |         |
| Basal cortisol, μgr/dL| 3.73    | 2.1     | 0.6     | 4.52    | <1      | <1      | 7.85    |
| Basal ACTH, pg/mL    | <5      | 7.48    | 15.3    | 19      | <5      | 19.5    | 37      |
| Stimulated cortisol, μgr/dL | ND   | 5.4     | 6.21    | 16.3    | ND      | 3       | 9.44    |
| Abdominal USG        | Splenomegaly | Bilateral nephrocalcinosis | Hepatosteatosis grade 2 | Normal | NA | Normal | NA |

Other

Normalization time of the HPA axis, day

|                     | BMD-SD L1-L4: -0.2 |
|---------------------|---------------------|
| 1                   | 40                  |
| 2                   | None                |
| 3                   | 150                 |
| 4                   | 51                  |
| 5                   | Unknown             |
| 6                   | 60                  |
| 7                   | Unknown             |

Therapy

|                      |                         |                         |                         |                         |                         |                         |                         |
|----------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                      | MPZ started as 15 mg/m²/d | Splenectomy for ITP; metformin for hyperglycemia | HC started as 20 mg/m²/d and FC 0.1 mg/d for adrenal atrophy; furosemide and pamidronate for hypercalcemia | HC started as 20 mg/m²/d | None | Parents refused to all investigations and therapy | HC started as 20 mg/m²/d | HC started as 20 mg/m²/d |
|                      |                         |                         |                         |                         |                         |                         |                         |
|                      |                         |                         |                         |                         |                         |                         |                         |

HC: hydrocortisone, FC: fludrocortisone, PR: prednisolone, MPZ: methylprednisolone, 25-(OH)D₃: 25-hydroxyvitamin D, 1,25-(OH)₂D₃: 1,25-dihydroxyvitamin D, PTH: parathormon, AST: aspartate transaminase, ALT: alanine transaminase, ALP: alkaline phosphatase, TC: total cholesterol, LDL: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, MPZ: methylprednisolone, TG: triglyceride, HC: hydrocortisone, USG: ultrasonography, HPA: hypothalamo-pituitary-adrenal, BMD: bone mineral density, SD: standard deviation, OGTT: oral glucose tolerance test, NA: not applicable, ND: not defined.
The majority of them were exposed to topical potent-GCs with unpredictable dosage, due to the route of application.

Topical GCs with mild and moderate potency, used in children to treat atopic dermatitis, have rarely been demonstrated to suppress the HPA axis, even if used for a long time (16,17). However, potent or high-potency topical GCs or combinations of other GCs are well recognized to negatively correlate with cortisol response in the LD-ACTH test (17). Suppression of the HPA axis is dose dependent after systemic GC treatment (18). In older children, potent GCs usually cause mild to moderate AI, to a greater degree than HC would, but they rarely cause severe AI (16).

Although obesity is an expected finding in patients with CS, seven patients had a BMI SDS < +2 in this study, the three infants and one child. Two of these infants were underweight for their age. The reasons for not gaining weight, such as

| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|---|---|----|----|----|----|----|
| 24 | 29.9 | 40.5 | 11.2 | 10.1 | 10.9 | 4.9 |
| 148 | 148 | 3 | 23 | 46 | 14 | 50 | 22 | 80 | 15 | 22 |
| 22 | 31 | 17 | 29 | 28 | 294 | 228 | 372 |
| 140 | 230 | 138 | 137 | 140 | 102 | 124 | NA | NA | 75 |
| 70 | 153 | 52 | 74 | 42 | 62 | 61 | 48 |
| 19 | 16.9 | 9.1 | 1.0 | 5 | 5 | 5 | 35.2 | 56 |
| 4.57 | 12.6 | 6 | 1.1 | 18.1 | 21.2 |

| Hepatosteatosis, hepatosplenomegaly | Hepatosteatosis grade 1, nephrocalcinosis at right kidney | Hepatosteatosis grade 2, hepatomegaly |
|---|---|---|
| Hyperinsulinism at the OGTT | Spot urine Ca/creatinin ratio: 1.12 | BMD-SD L1-L4: -0.6 |
| 780 | 240 | 30 |
| HC started as 20 mg/m²/d | PR equivalent to 20 mg/m²/d hydrocortisone | HC started as 20 mg/m²/d |
| HC started as 20 mg/m²/d | HC started as 20 mg/m²/d | HC started as 20 mg/m²/d |
| HC started as 20 mg/m²/d | HC started as 20 mg/m²/d | HC started as 20 mg/m²/d |
| HC started as 20 mg/m²/d | HC started as 20 mg/m²/d | HC started as 20 mg/m²/d |

Table 2. Laboratory findings in the patients

| 25-(OH)D | 1,25-(OH)D | P, mg/dL | Ca, mg/dL | Insulin, μIU/mL | Fasting glucose, mg/dL |
|---|---|---|---|---|---|
| 15-90 | 15-90 | 15-90 | 15-90 | 15-90 | 15-90 |
malabsorption, food intolerance, or gastroesophageal reflux in these patients could not be investigated. The reason for weight loss may be central AI caused by suppression of the HPA axis by potent GCs. Anorexia, nausea, and weight loss are well-known signs of AI (19,20) and may be the reason for poor weight gain in these infants. In addition, the girl infant was born prematurely, was followed up in the neonatal intensive care unit and had a history of cardiac arrest on the 4th day of her life. She was being followed up with a diagnosis of ichthyosis since birth. On admission, she was still being treated with a number of potent GCs simultaneously by the dermatologist. At presentation there was no sign of catch-up growth. These findings do not permit comment on the underlying reasons for failure to gain weight in infants in this study.

In this study, AI was absent on admission in two patients who were exposed to potent steroids. Clobetasol-containing pomade was not applied to case 13 for two months prior to presentation. Although she was obese, the cause of the absence of AI on LD-ACTH test was the improvement in the HPA axis within these two months. Oral MPZ was given to case 14 for treatment of asthma for a month. A month before his admission, MPZ treatment was abruptly stopped due to weight gain. In this patient, AI was not detected at admission since the duration of MPZ usage was short and it is possible that HPA axis function improved within this one month respite from MPZ therapy. Depending on the dosage of GCs, the route of administration, and the duration of drug administration, complete recovery of the HPA axis after discontinuation may vary from one week to several weeks (12,13,14,15). We hypothesize that the reason that AI was not detected following ICS in these patients was the complete recovery of HPA in the period between discontinuation of GC and their admission to the clinic.

The metyrapone test is not recommended in the diagnosis of AI in children, and is even more strongly discouraged in infants, since it could trigger adrenal crisis. Furthermore, the insulin tolerance test (ITT) is inconvenient in younger children, and in patients with a history of seizure or cardiac insufficiency (21). Since both the ITT and the metyrapone test carry major risks, such as precipitating acute AI, corticotrophin analog stimulation test has been introduced. The LD (1 μg of corticotrophin) ACTH stimulation test is easier to perform than the ITT and carries a very low risk of side effects (10,22). In a recent study in adults, the stimulated cortisol values of the 1 mcg ACTH test were compared and it was suggested that the number of false positive patients would be significantly reduced by accepting the stimulated cortisol cut-off value of 401.5 nmol/L (14.55 mcg/dL) instead of 500 nmol/L (18.12 mcg/dL) (23). However, in studies conducted in children, it was stated that values above 500 nmol/L (8) or 550 nmol/L (24) of stimulated cortisol in the 1 mcg ACTH test may exclude AI. In this study, in 10 of the 12 patients tested, the stimulated cortisol response was inadequate, whereas in only two patients, stimulated cortisol was greater than 18 mcg/dL.

It has been shown that GCs increase lipid production in rats and also increase circulating TG, as well as resulting in hepatosteatosis (25). GCs increase the conversion of carbohydrates to fatty acids in hepatocytes, and decrease fatty acid oxidation and also cause an increase in the synthesis of TG in hepatocytes using increased fatty acids (26). In the liver of a baby with AI caused by topical clobetasol propionate, we demonstrated for the first time that macrovesicular fat was present in the liver (6). After our original report, a subsequent study regarding non-alcoholic hepatosteatosis (NAFLD) detected by ultrasonography in infants with ICS was published (5). In the present series, NAFLD was detected in six of 11 patients who had ultrasonographic examination. The youngest patient with NAFLD was 2.2 months old, while the others were older than nine years. The mother of the baby with NAFLD was applying a cream to prevent diaper dermatitis. Blood and urine samples taken before treatment revealed that the synthesis of this patient’s endogenous steroids was suppressed. Since this patient had not been prescribed any GC treatment, it was suggested that the cream used for diaper dermatitis contained potent GC. Misuse of a potent corticosteroid was responsible for hepatosteatosis in our patients. Hypertriglycerideremia, as well as an increase in transaminases, are expected findings in patients with NAFLD (26,27). In the present study, increased transaminase associated with hypertriglycerideremia level was detected in an infant without NAFLD. Interestingly, serum lipids and transaminases were normal in another infant with NAFLD. Among the patients presented here, hypertriglycerideremia was detected in two thirds of the patients in whom this was measured. These abnormal lipid profiles might be due to exposure to potent GCs.

Hypercalcemia has been reported in patients with primary or secondary AI (28,29,30). In addition, the reduction of glomerular filtration due to fluid loss in adrenal crisis, acute kidney injury and hypercalcemia were also found in adult patients (31,32,33). Decreased glomerular filtration results in a reduced filtered load of calcium, and increased calcium renal reabsorption occurs, due to volume depletion in AI. Enhanced calcium mobilization from bone in AI also contributes to the development of hypercalcemia. The
postulated mechanism for AI to cause hypercalcemia is through a combination of increased calcium flux into the extracellular space and reduced calcium renal excretion (34). Stanniocalcin, secreted from the adrenal gland, reduces circulating calcium (35). The level of calcium is also reduced due to a decreased production in stanniocalcin in the state of AI. Endogenous GCs decrease the absorption of calcium from the intestines and increase the excretion of calcium in the urine (36). It is postulated that increased calcium absorption is caused by GC insufficiency (37) and GC replacement therapy has been shown to improve hypercalcemia.

In the presented series, hypercalcemia was detected in two infants. Both patients were less than three months old and had been exposed to GCs since the first days of their lives. Vitamin D hypervitaminosis and subcutaneous fat necrosis were not detected in these patients. Nephrocalcinosis was found in both babies. Nephrocalcinosis persisted in one patient until the age of 2.5 years when he was lost to follow-up. CYP24A1 mutation was investigated in this patient and no mutation was detected. The other baby’s father also had nephrolithiasis. However, nephrocalcinosis resolved by 30 months of age in this second case. AI due to exposure to exogenous potent GCs may be the cause of nephrolithiasis in these infants.

Study Limitations
The first limitation was that not all patients were examined for possible side effects of GC, such as intracranial benign hypertension, osteoporosis, myopathy, glaucoma and neuropsychiatric symptoms (depression, mood changes). The second limitation was that not all cases could be followed up for a long time.

Conclusion
This study highlights, yet again, the high frequency of AI in children exposed to high-dose oral and topical potent GCs. Recovery of HPA axis function from this AI may be as long as 780 days in children. It is notable that NAFLD was detected even in very young infants exposed to potent GC. It should be also kept in mind that hypercalcemia and nephrocalcinosis may be detected following exposure to potent GC. Clinicians should alert parents to the potentially serious side effects, when prescribing GC to their children.

Acknowledgement
The author are grateful to Prof. Dr. Wiebke Artl and her team for gratis analysis of urine steroids of case 12 presented in this study.

Ethics

Ethics Committee Approval: The hospital ethics committee approved this study (Zeynep Kamil Women and Children Diseases Training and Research Hospital Clinical Research Ethics Committee, 116/18.12.2019).

Informed Consent: Written informed consent was obtained from the parents.

Peer-review: Externally peer-reviewed.

Financial Disclosure: The author declared that this study received no financial support.

References
1. Stratakis CA. An update on cushing syndrome in pediatrics. Ann Endocrinol (Paris) 2018;79:125-131. Epub 2018 Apr 9
2. Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int J Mol Sci 2017;18:2201.
3. Crowley RK, Argese N, Tomlinson JW, Stewart PM. Central hypoadrenalism. J Clin Endocrinol Metab 2014;99:4027-4036.
4. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:2171-2180. Epub 2015 Apr 6
5. Güven A, Gülümser O, Ozgen T. Cushing’s syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab 2007;20:1173-1182.
6. Güven A, Karadeniz S, Aydin O, Akbalik M, Aydin M. Fatal disseminated cytomegalovirus infection in an infant with Cushing’s syndrome caused by topical steroid. Horm Res 2006;64:35-38. Epub 2005 Aug 2
7. Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum 2016;46:133-141. Epub 2016 Mar 9
8. Barillas JE, Eichner D, Van Wagoner R, Speiser PW. Iatrogenic cushing syndrome in a child with congenital adrenal hyperplasia: erroneous compounding of hydrocortisone. J Clin Endocrinol Metab 2018;103:7-11.
9. Demir K, Konaşçı E, Özçay G, Kasap Demir B, Özen S, Aydin M, Darendeliler F. New features for child metrics: further growth references and blood pressure calculations. J Clin Res Pediatr Endocrinol 2020;12:125-129. Epub 2019 Sep 2
10. Weintraub N, Sprecher E, Josefson Z, Weininger C, Aurbach-Klipper Y, Lazard D, Karp M, Pertzelan A. Standard and low-dose short adrenocorticosterone test compared with insulin-induced hypoglycemia for assessment of the hypothalamic-pituitary-adrenal axis in children with idiopathic multiple pituitary hormone deficiencies. J Clin Endocrinol Metab 1998;83:88-92.
11. Axelrod L. Perioperative management of patients treated with glucocorticoids. Endocrinol Metab Clin North Am 2003;32:367-383.
12. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000;355:542-545.
13. Zora JA, Zimmerman D, Carey TL, O’Connell EJ, Yunginger JW. Hypothalamic-pituitary-adrenal axis suppression after short-term, high-dose glucocorticoid therapy in children with asthma. J Allergy Clin Immunol 1986;77:9-13.
14. Mendoza-Cruz AC, Wargon O, Adams S, Tran H, Verge CF. Hypothalamic-pituitary-adrenal axis recovery following prolonged prednisolone therapy in infants. J Clin Endocrinol Metab 2013;98:E1936-E1940. Epub 2013 Sep 30
15. Morris HG, Jorgensen JR. Recovery of endogenous pituitary-adrenal function in corticosteroid-treated children. J Pediatr 1971;79:480-488.
16. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-484.
17. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105:794-799.
18. Turpeinen M. Adrenocortical response to adrenocorticotropic hormone in relation to duration of topical therapy and percutaneous absorption of hydrocortisone in children with dermatitis. Eur J Ped 1989;148:729-731.
19. Cortet C, Barat P, Zenaty D, Guignat L, Chanson P. Group 5: Acute adrenal insufficiency in adults and pediatric patients. Ann Endocrinol (Paris) 2017;78:535-543. Epub 2017 Nov 23
20. Bowden SA, Henry R. Pediatric Adrenal Insufficiency: Diagnosis, Management, and New Therapies. Int J Pediatr 2018;2018:1-8.
21. Gonc EN, Kandemir N, Kink ST. Significance of low-dose and standard-dose ACTH tests compared to overnight metyrapone test in the diagnosis of adrenal insufficiency in childhood. Horm Res 2003;60:191-197.
22. Rose SR, Lustig RH, Burstein S, Pituchcheewanont P, Broome DC, Burghen GA. Diagnosis of ACTH deficiency. Comparison of overnight metyrapone test to either low-dose or high-dose ACTH test. Horm Res 1999;52:73-79.
23. MongioÌì LM, Condorelli RA, Barbagallo F, Cannarella R, La Vignera S, Calogero AE. Accuracy of the low-dose ACTH Stimulation test for adrenal insufficiency diagnosis: a re-assessment of the cut-off value. J Clin Med 2019;8:806.
24. Glenny HP, Brindley DN. The effects of cortisol, corticotropin and thyroxine on the synthesis of glycerolipids and on the phosphatidate phosphohydrolase activity in rat liver. Biochem J 1978;176:777-784.
25. Magomedova L, Cummins CL. Glucocorticoids and metabolic control. Handb Exp Pharmacol 2016;233:73-93.
26. Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol 2015;154:94-103. Epub 2015 Aug 1
27. Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci 2016;17:947.
28. Nerup J. Addison’s disease-clinical studies. a report of 108 cases. Acta Endocrinol 1974;76:127-141.
29. Wong RK, Gregory R, Lo TC. A case of isolated ACTH deficiency presenting with hypercalcaemia. Int J Clin Pract 2000;54:623-624.
30. Harano Y, Kitano A, Akiyama Y, Kotajima L, Honda K, Arioka H. A case of isolated adrenocorticotropic hormone deficiency: a rare but possible cause of hypercalcaemia. Int Med Case Rep J 2015;8:77-79.
31. Bhatti RS, Flynn MD. Adrenal insufficiency secondary to inappropriate oral administration of topical exogenous steroids presenting with hypercalcaemia. BMJ Case Rep 2012;2012:bcr0320125983.
32. Sakao Y, Sugita T, Tsuji T, Ohashi N, Yasuda H, Fujigaki Y, Kato A. Clinical manifestation of hypercalcemia caused by adrenal insufficiency in hemodialysis patients: a case-series study. Intern Med 2014;53:1485-1490.
33. Ahn SW, Kim TY, Lee S, Jeong JY, Shim H, Han YM, Choi KE, Shin SJ, Yoon HE. Adrenal insufficiency presenting as hypercalcaemia and acute kidney injury. Int Med Case Rep J 2016;9:223-226.
34. Muls E, Bouillon R, Boelaert J, Lamberigts G, Van Imschoot S, Daneeles R, De Moor P. Etiology of hypercalcaemia in a patient with Addison’s disease. Calcif Tissue Int 1982;34:523-526.
35. Miura W, Mizunashi K, Kimura N, Koide Y, Noshiro T, Miura Y, Furukawa Y, Nagura H. Expression of stanniocalcin in zona glomerulosa and medulla of normal human adrenal glands, and some adrenal tumors and cell lines. APMIS 2000;108:367-372.
36. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994;9:1097-1105.
37. Walker DA, Davies M. Addison’s disease presenting as a hypercalcemic crisis in a patient with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 1987;14:419-423.